DHFL aside, pharma to drive Piramal stock

The company’s management has guided for a 15 per cent organic revenue growth in the pharma business for FY22 compared with the 1 per cent growth in the first nine months of FY21.

https://ift.tt/307zN8a

Post a Comment

0 Comments